Executive Medical Director, Oncology Drug Development

Incyte; Wilmington (DE); On-site; USD 180,000 - 290,000; Full time

Benefits offered by this job

Equal opportunity employer

Job summary

Incyte in Wilmington, Delaware seeks a Senior Director - Executive Medical Director, Drug Development to lead clinical drug development for oncology products from Phase I to III. The role requires directing investigator-initiated trials, maintaining high ethical and regulatory standards, and coordinating with medical affairs for future antineoplastic launches.

The position emphasizes collaboration with CROs, regulatory bodies like FDA/EMA, and internal teams to shape study design, protocols, and

Qualifications

• MD or DO with 3–5 years of oncology drug development experience.
• Board-certified or eligible in Oncology preferred.
• Ability to multi-task and work in a dynamic environment.
• Excellent written and verbal communication skills.

Responsibilities

• Provide guidance for investigator-initiated trials related to product development and life cycle management of a compound.
• Ensure highest ethical and regulatory standards during investigation and development of anticancer agents.
• Collaborate with medical affairs for successful launch of future antineoplastic agents.
• Detect and analyze emergent issues during clinical drug development and develop mitigating strategies.
• Represent Incyte at key national and international medical and scientific meetings.

Skills

Oncology drug development

Multitasking

Written and verbal communication

Leadership potential

Education

MD/DO degree

Job description

Incyte in Wilmington, Delaware seeks a Senior Director - Executive Medical Director, Drug Development to lead clinical drug development for oncology products from Phase I to III. The role requires directing investigator-initiated trials, maintaining high ethical and regulatory standards, and coordinating with medical affairs for future antineoplastic launches.

The position emphasizes collaboration with CROs, regulatory bodies like FDA/EMA, and internal teams to shape study design, protocols, and